Abstract D2C7-(scdsFv)-PE38KDEL (D2C7-IT) is a novel recombinant Pseudomonas exotoxin A-based immunotoxin (IT), targeting both wild-type epidermal growth factor receptor (EGFRwt) and mutant EGFR variant III (EGFRvIII) proteins overexpressed in glioblastomas. Initial pre-clinical testing demonstrated the anti-tumor efficacy of D2C7-IT against orthotopic glioblastoma xenograft models expressing EGFRwt, EGFRvIII, or both EGFRwt and EGFRvIII. A good laboratory practice (GLP) manufacturing process was developed to produce sufficient material for a phase I/II clinical trial. D2C7-IT was expressed under the control of the T7 promoter in Escherichia coli BLR (λ DE3). D2C7-IT was produced by a 10-L batch fermentation process and was then purified from inclusion bodies using anion exchange, size exclusion, and an endotoxin removal process that achieved a yield of over 300 mg of purified protein. The final vialed batch of D2C7-IT for clinical testing was at a concentration of 0.12 ± 0.1 mg/mL, the pH was at 7.4 ± 0.4, and endotoxin levels were below the detection limit of 10 EU/mL (1.26 EU/ mL). The stability of the vialed D2C7-IT has been monitored over a period of 42 months through protein concentration, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), isoelectric focusing, size exclusion chromatography, cytotoxicity, sterility, and pH measurements. The vialed D2C7-IT is currently being tested in a phase I/II clinical trial by intratumoral convection-enhanced delivery for 72 h in patients with recurrent glioblastoma (NCT02303678, D2C7 for Adult Patients with Recurrent Malignant Glioma; clinicaltrials.gov).
Introduction
The epidermal growth factor receptor (EGFR), a 170-kDa, transmembrane glycoprotein, is a member of the ErbB/ EGFR family of receptor tyrosine kinases (RTKs). The overexpression of EGFR is reported in head and neck cancer (Rubin Grandis et al. 1996) , breast cancer (Klijn et al. 1992) , ovarian carcinoma (Bartlett et al. 1996) , lung cancer (Pavelic et al. 1993) , prostate cancer (Fox et al. 1994) , and brain tumors (Libermann et al. 1984; Arita et al. 1989 ). Compared to normal control brain specimens, a 300-fold overexpression of EGFR is observed in glioma (Libermann et al. 1985) . Comprehensive molecular analyses have identified mutation, rearrangement, altered splicing, and/or focal amplification of EGFR in 57% of glioblastoma patients (Brennan et al. 2013 ).
In the absence of gene amplification, EGFR protein overexpression has also been demonstrated in glioblastoma (Chaffanet et al. 1992) .
The EGFR gene amplification is often associated with gene rearrangements. The most common rearrangement is the EGFR variant III (EGFRvIII) mutant, which is present in 67% of glioblastomas with EGFR amplification (Frederick et al. 2000) . The high prevalence of EGFR fusion and deletion variants in glioblastomas necessitates the development of a therapeutic strategy that will target the different EGFR alterations that exist concurrently in a tumor. An agent targeting multiple variants of EGFR is expected to have a major impact on the survival of glioblastoma patients.
Pseudomonas exotoxin A (PE), secreted by Pseudomonas aeruginosa, is a potent toxin that can be chemically or genetically fused to monoclonal antibodies (mAbs) or mAb fragments targeting tumor-specific proteins (Weldon and Pastan 2011) . These mAb-toxin chimeras specifically targeting and eliminating tumor cells are called immunotoxins (ITs) . Recombinant ITs are produced by genetically fusing a 38-kDa truncated mutant form of PE, PE38KDEL, to the single-chain variable-region antibody fragments (scFvs), consisting of the heavy-and light-chain variable regions (VH and VL) (Seetharam et al. 1991) . D2C7-(scdsFv)-PE38KDEL (D2C7-IT) is a novel recombinant IT with dual specificity for the EGFRwt and mutant EGFRvIII proteins (Chandramohan et al. 2013 ). In pre-clinical studies, the dualspecific immunotoxin D2C7-IT demonstrated a strong antitumor response against intracranial glioblastoma xenografts expressing either EGFRwt (prolonged survival by 310%, P = 0.006) or both EGFRwt and EGFRvIII (prolonged survival by 166%, P = 0.001) (Chandramohan et al. 2013 ). D2C7-IT (single dose) is currently being evaluated in a phase I clinical trial (NCT02303678) to determine the maximum tolerated dose when delivered intratumorally by convectionenhanced delivery for 72 h to recurrent grade III (dose escalation only) and IV (dose escalation and dose expansion) malignant glioma patients and to determine the optimal dose for a subsequent single-arm phase II trial.
In this report, we describe the production, purification, and stability testing processes of the clinical grade D2C7-IT, which was manufactured under good laboratory practice (GLP) conditions.
Materials and methods
Production of D2C7-IT was performed by the Antibody Engineering and Antibody Therapeutics (AEAT) Program personnel at the Duke University Medical Center AEAT Production Facility. All materials were purchased at the highest purity possible, and certificates of analysis from different manufacturers were retained. All equipment was cleaned and tested in accordance with GLP guidelines. All of the AEAT Program personnel were trained on and followed the GLP guidelines during production of the clinical grade D2C7-IT.
D2C7-IT strain construction
Plasmid (pRB199-D2C7-scdsFv-PE38KDEL) expressing D2C7-IT has been previously described (Chandramohan et al. 2013) . The pRB199-D2C7-scdsFv-PE38KDEL plasmid was transformed into the expression host E. coli BLR (λ DE3) (Novagen-EMD Millipore, Billerica, MA), and positive clones were selected by chloramphenicol resistance. Ten colonies were picked and inoculated into tubes (11CT-20CT) containing 3 mL of Luria-Bertani (LB) broth with 75 μg/mL chloramphenicol and 12.5 μg/mL tetracycline. All clones were incubated overnight at 37°C in a rotary shaker at 250 rpm. Two-hundred microliters of clones 11CT-20CT was seeded into tubes with 3 mL of Turbo Prime-olate media (Athena Environmental Sciences Inc., Baltimore, MD) with chloramphenicol and tetracycline and incubated at 37°C in a rotary shaker at 250 rpm. After 2 h of incubation, 3 mL of 40% glycerol was added to all the tubes and six 1-mL aliquots were stored frozen at −80°C (Accession Cell Bank [ACB] clones). One frozen ACB vial of cells per clone was thawed, and 300 μL of the bacterial stock was added to a tube containing turbo prime-olate media with chloramphenicol and tetracycline and incubated for 6 h at 37°C in a rotary shaker at 250 rpm. Cultures were induced with 1 mM isopropyl β-Dthiogalactoside (IPTG) overnight at 37°C in a rotary shaker at 250 rpm, and inclusion body pellets were analyzed in a NuPage 4-12% Bis-Tris gels (Thermo Fisher Scientific, Waltham, MA) for protein expression.
Production of D2C7-IT master cell bank
One ACB vial of clone 18CT (DsD2C7-PE38-KDEL clone 18CT BLR [DE3]) was thawed into 25 mL of Animal Product-Free Terrific Broth media (Teknova, Hollister, CA) and incubated in a rotary shaker overnight at 250 rpm at 37°C. The following day, 25 mL of the overnight culture of clone 18CT was added to 150 mL of fresh Animal ProductFree Terrific Broth media and incubated in a rotary shaker at 250 rpm at 37°C until the OD 600 was 0.845. Master cell bank (MCB) vials of D2C7-IT (DsD2C7-PE38-KDEL MCB of clone 18 in E. coli BLR [DE3] 3-13-12) were prepared by combining 800 μL of clone 18CT bacterial culture with 200 μL of 100% glycerol per vial.
The following quality control testing of the D2C7-IT MCB was performed by Charles River Biopharmaceutical Services, Malvern, PA; Pennsylvania State University-Gastroenteric Disease Center, University Park, PA; and Genewiz, South Plainfield, NJ:
1. Bacterial purity, the purity of the D2C7-IT MCB microbial culture was determined through growth in differential agars, viability testing of microbial suspension, and gene copy number analysis by amplification of specific nucleic acids utilizing fluorescent probes (Charles River Biopharmaceutical Services). 2. Bacterial identity, the strain of E. coli used for MCB production was verified through pulse field gel electrophoresis (PFGE) (Pennsylvania State University), comparative sequence analysis of genomic DNA encoding gyrase B, and retention of selectable markers in transformed host cell lines (Charles River Biopharmaceutical Services). 3. Plasmid identity, identity of the transformed pRB199-D2C7-scdsFv-PE38KDEL plasmid was confirmed through the retention of the recombinant construct in transformed E. coli cell lines, restriction endonuclease analysis of the plasmid DNA by agarose gel electrophoresis and ethidium bromide staining (Charles River Biopharmaceutical Services), and isolation and sequencing of the pRB199-D2C7-(scdsFv)-PE38KDEL plasmid from the master cell bank by Genewiz (South Plainfield, NJ). 4. Safety, the safety of the MCB was established by the testing for Shiga-like toxin/toxin genes (Pennsylvania State University), the induction of bacterial virus from E. coli using mitomycin C, and the ultrastructural evaluation of fluid samples for bacteriophage particles by negative staining (Charles River Biopharmaceutical Services).
D2C7-IT fermentation
One frozen MCB vial was thawed, and 0.2 mL of bacterial cells was inoculated into 2.0 mL of SOC media and incubated for 2 h at 220 rpm and 37°C. The cells were then plated on ten LB-chloramphenicol (75 μg/mL) plates and incubated at 37°C overnight. The ten plates of grown bacteria were inoculated into two 2-L shake flasks, each containing 500 mL of sterile, prepared Animal Product-Free Terrific Broth media (Teknova) supplemented with 4.1 mM MgSO 4 , 0.5% glucose, and chloramphenicol at 34 μg/mL. The inoculated seed flasks were incubated at 230 rpm and 37°C. When the optical density at 600 nm (OD 600 ) of seed culture reached an OD 600 ≈ 1, both the seed flasks were pooled to yield a 12.5% inoculum for the fermentor. A 10-L fermentor was prepared for fermentation of the D2C7-IT by batching the fermentor with 7 L of Terrific Broth media, 2% glucose, 0.05% magnesium sulfate, and 34 μg/mL chloramphenicol. The final volume in the fermentor was 8 L. The fermentor was set to culture parameters as follows: agitation cascade, temperature 37°C (36.5-37.5°C), pH 7.0-7.2, dissolved oxygen ≈70%, and antifoam as required. The prepared media in the fermentor was inoculated with the prepared D2C7-IT seed culture. The D2C7-IT fermentation culture was sampled hourly for OD 600 measurement. D2C7-IT expression was induced with 1 mM IPTG for 2 h when the OD 600 reached 6 ± 1 (Fig. 1 ). Cells were harvested by centrifugation, and the paste was stored at −20°C overnight or until lysis.
Inclusion body preparation
Thawed cell paste (30 g each) was resuspended in 100 mL of 50 mM Tris-HCl pH 7.5 buffer and dispersed through homogenization. Next, 0.5 mL of 1 M MgSO 4 (5 mM final concentration), 6000 u of DNase I, and 300 mg of lysozyme (10 mg/g bacterial pellet) were added to the dispersed cell mixture and incubated at room temperature for 1 h. Twelve milliliters of 5 M NaCl (500 mM final concentration) and 9.6 mL of 25% Triton X-100 buffer (2% final concentration) were added to the bacterial lysate, which was then homogenized and incubated at room temperature for 30 min. Finally, 4 mL of 0.5 M ethylenediaminetetraacetic acid (EDTA) (16.7 mM final concentration) was added to the bacterial lysate, and the final volume was adjusted to 200 mL with 2% Triton-X 100 in TE 50/20 buffer (50 mM Tris-HCl pH 7.5 and 20 mM EDTA), dispersed thoroughly by homogenization, and centrifuged at 10,000 rpm at 4°C for 50 min. The bacterial pellets were washed (200 mL total volume) twice with 2% Triton-X 100 in TE 50/20 buffer and three times with TE 50/20 buffer. During each wash step, the bacterial pellet was thoroughly dispersed through homogenization followed by centrifugation, at 10,000 rpm at 4°C for 50 min. The final inclusion body pellets were labeled and stored at −20°C until solubilization.
Inclusion body solubilization and D2C7-IT refolding
Individual inclusion body pellets were dissolved in solubilization buffer (6 M guanidine-HCl) overnight at room temperature on a shaker. The solubilized inclusion body was centrifuged at 16,000 rpm at 4°C for 50 min. The resulting supernatant was collected, and the protein concentration was determined by Pierce Coomassie Plus (Bradford) Assay Kit (Thermo Fisher Scientific). The solubilized inclusion body was then diluted to a concentration of 10 mg/mL using an appropriate volume of the solubilization buffer. Solubilized D2C7-IT was then reduced by the addition of dithioerythritol (DTE; Sigma, St. Louis, MO) to 10 mg/mL for the final concentration and incubated for 16 h at room temperature with gentle shaking. Reduced D2C7-IT was slowly diluted 100-fold into refolding buffer (100 mM Tris-HCl pH 8.0, 0.5 M L-arginine-HCl, 0.9 mM oxidized form of glutathione, 2 mM EDTA, 2 mL of Protease Inhibitor/L [Sigma], pH 10.3) with gentle mixing. The refolding reaction was allowed to proceed for 72 h at 2-8°C without agitation.
Dialysis, filtration, and purification of D2C7-IT
The refolded protein solution (3-5 L) was dialyzed against 50 L of dialysis buffer (100 mM Urea, 20 mM Tris-HCl, pH 7.5) overnight at 2-8°C. The dialyzed retentate was filtered through a 0.22-μm bottle top filter for subsequent purification.
A high-resolution (HR16/10) column (GE Healthcare) was packed with Q-Sepharose High Performance (HP) anion exchange resin (GE Healthcare) and had a packed bed volume of 20 mL. The Q Sepharose HP column was equilibrated with ten column volumes (CVs) of buffer A (20 mM Tris-HCl, pH 7.5) until the conductivity of the effluent was within 2 mS/cm of the equilibration buffer. The column was then run at a flow rate of 6 mL/min. The D2C7-IT Q-Sepharose HP load (4-6 L of dialyzed and filtered protein solution) was applied to the QSepharose HP column, and the flow-through was collected. After washing the Q-Sepharose HP column with five CVs of buffer A (20 mM Tris-HCl, pH 7.5), the D2C7-IT was eluted (flow rate, 4 mL/min/fraction; total runtime, 60 min) using a linear gradient of buffer B (20 mM Tris-HCl, pH 7.5, 1 M NaCl), with tubes 1-10 collecting fractions with 0-10% buffer B, tubes 11-50 collecting fractions with 10-50% buffer B, and tubes 51-60 collecting fractions with 50-100% buffer B. The main D2C7-IT-containing fractions eluted from QSepharose HP chromatography were pooled based on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis and processed for high performance liquid chromatography-size exclusion chromatography (HPLC-SEC) purification.
Pooled Q-Sepharose D2C7-IT Q-Sepharose fractions were concentrated using a 30-kDa molecular weight cutoff (MWCO) Vivaspin 20 ultrafiltration device (Sartorius, Bohemia, NY). Pooled D2C7-IT fractions were concentrated to approximately 4 to 6 mg/mL and dialyzed (using autoclaved Spectra/Por 25-kDa MWCO dialysis tubing) overnight against filter sterilized (VacuCap filters, Pall Corporation, Port Washington, NY) endotoxin low TSK buffer (70 mM Na 2 HPO 4 , 62.5 mM NaH 2 PO 4 , and 100 mM Na 2 SO 4 , pH 6.7), which was prepared using sterile intravenous injection water. Dialyzed D2C7-IT was then filtered through a 0.2-μm Millex GV filter (EMD Millipore) and run on a TSKgel SuperSW3000 (particle size 4 μm, 21.5 mm × 30 cm; Tosoh Bioscience, King of Prussia, PA) gel filtration column equilibrated with TSK buffer. The column was run at a flow rate of 2 mL/min (total runtime 60 min), and when a stable base line was obtained, a 1 mL D2C7-IT sample was injected and 30-s fractions were collected under sterile conditions. The main D2C7-IT-containing fractions eluted from the TSKgel SuperSW3000 gel filtration column were pooled based on SDS-PAGE analysis, concentrated, and filtered through a 0.2-μm Millex GV filter for endotoxin removal.
A 1 × 10-cm Econo-Column chromatography column (Bio-Rad, Hercules, CA) was packed with ActiClean Etox resin (Sterogene, Carlsbad, CA). The column was equilibrated with ten CVs of 1 N NaOH and incubated over night at 4°C. The column was then rinsed with 20 CVs of sterile intravenous injection water and equilibrated with 5 CVs of TSK buffer (filtered through 0.2-μm Acrodisc Units with Mustang E Membrane for endotoxin removal; Pall Corporation). Concentrated D2C7-IT was passed over the ActiClean Etox column at a flow rate of 1 mL/min for endotoxin removal. The D2C7-IT eluate from the ActiClean Etox column was then dialyzed overnight at 4°C against Cell Therapy Systems DPBS CTS without Calcium Chloride without Magnesium Chloride (Thermo Fisher Scientific). Purified individual bulk lots of D2C7-IT were transferred to 50 mL conical tubes, labeled, and stored at −80°C.
Preparation of final purified bulk D2C7-IT product
The final purified bulk product was made by combining purified intermediate bulk lots. Individual purified intermediate bulk lots were filtered through a 0.2-μm Millex GV filter and combined into one purified bulk lot. The protein concentration of the bulk lot was assessed by Pierce Coomassie Plus (Bradford) Assay, and the volume was adjusted to yield a final concentration of approximately 120 μg/mL using DPBS CTS pH 7.4.
D2C7-IT analytical release testing
The analytical tests performed on the final purified bulk D2C7-IT product for release to Compounding Pharmacy for vialing are described below.
Color, appearance, and clarity by visual inspection
The final purified bulk D2C7-IT product was assessed by visual inspection to determine if the soluble product in the liquid formulation was free from any particulate matter, opaqueness, and/or tint or turbidity of the solution.
Identity by SDS-PAGE
SDS-PAGE (non-reduced and reduced) analysis was performed using NuPAGE Novex 4-12% Bis-Tris pre-cast polyacrylamide gels (Thermo Fisher Scientific) to estimate the molecular weight and identity of the final bulk D2C7-IT product. The final bulk D2C7-IT product ran on NuPAGE gel was visualized by staining with GelCode Blue Stain Reagent (Thermo Fisher Scientific). Molecular weight standards (Precision Plus Protein Dual Color Standards; Bio-Rad) were included on the same gel in order to determine the molecular weight of the purified bulk product through relative electrophoretic mobility comparison with that of the standards.
Protein concentration by Pierce Coomassie Plus (Bradford) Assay
Pierce Coomassie Plus (Bradford) Assay was used to determine the protein concentration of the final purified bulk D2C7-IT product. Bovine serum albumin (BSA) was used to prepare a known protein concentration reference standard in the same diluent as the final purified bulk D2C7-IT product. Diluted standards and the D2C7-IT sample were added to the Pierce Coomassie Plus Reagent, incubated at ambient temperature for 5-10 min, and the optical density of the samples were measured at 595 nm in a spectrophotometer. The protein concentration of the final purified D2C7-IT product was determined using the BSA reference standard curve.
Potency testing by cytotoxicity in NR6M and A431p cell lines
The cytotoxic activity of the final purified bulk product was determined using the CellTiter-Fluor Cell Viability Assay Reagent (Promega, Madison, WI). The A431p (epidermoid carcinoma cell line expressing EGFRwt) and NR6M (Swiss 3T3 mouse fibroblast cell line transfected with the EGFRvIII) cells were cultured in ×1 Zinc Option (ZO) medium (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum. Cells were trypsinized, washed with ×1 phosphate-buffered saline (PBS), and counted with a hemocytometer. The cells were then seeded in 96-well plates at 5 × 10 3 (A431p) and 5 × 10 4 (NR6M) cells/well in 100 μL of the growth medium and incubated at 37°C, 5% CO 2 overnight. The final purified bulk D2C7-IT product was diluted in ×1 PBS-0.2% BSA and was added to the wells at an initial concentration of 1000 ng/ mL, followed by tenfold serial dilutions. The plates with A431p and NR6M cells were incubated at 37°C and 5% CO 2 for an additional 48 h. After the 48-h incubation period, CellTiter-Fluor Reagent (100 μL/well) was added and the plates were incubated for 70 min at 37°C and 5% CO 2 . The plates were then read at 400-nm excitation/505-nm emission. The data were analyzed using GraphPad Prism 4 software. The OD 505 values were averaged for the cells that were left untreated. One half of this average was considered as the 50% growth inhibition value. The concentration of the purified bulk D2C7-IT corresponding to the 50% growth inhibition value was reported as the IC 50 value.
Purity by HPLC-SEC
A TSKgel SuperSW3000 gel filtration column connected to a Beckman Coulter Gold HPLC system with pump module 126, detector module 168, and 32-karat software was utilized to assess the purity of the final bulk D2C7-IT product. The purified bulk D2C7-IT protein (12 μg) was injected into the SuperSW3000 SEC column. The eluate from the column was analyzed through a detector, and the absorbance (at 280 nm) was measured and used to create a chromatogram. From the area of the peak on the chromatogram, the percentages of the bulk D2C7-IT protein, aggregates, and cleavage fragments in the final product were determined.
Purity by isoelectric focusing
The purity of the final bulk D2C7-IT product was determined through isoelectric focusing (IEF). The isoelectric point (pI) of the bulk D2C7-IT was determined using Novex pH 3-10 IEF Protein Gels (Thermo Fisher Scientific), and the IEF Marker 3-10 (Thermo Fisher Scientific) was used as a reference standard.
DNA content (residual E. coli DNA)
The purity of the final bulk D2C7-IT product was determined through quantitation of residual E. coli DNA in the final purified bulk D2C7-IT product (Charles River Laboratories, Malvern, PA). Quantitative fluorescent PCR (QF-PCR) was used to detect the presence and quantity of residual E. coli DNA in the final purified bulk D2C7-IT product.
pH
The safety of the final purified bulk product was established through pH measurement. A Accumet AR-15 pH meter (Fisher Scientific) was calibrated using pH 4.0, 7.0, and 10.0 standard buffers. The probe was rinsed and blotted dry before determining the pH of the purified bulk D2C7-IT sample.
Endotoxin testing
A bacterial endotoxin assay was performed on the final purified bulk D2C7-IT product by the Duke University Hospital Radiopharmacy Laboratory. Endotoxin levels in the purified bulk D2C7-IT product were assessed through the Endosafe-PTS (Charles River Laboratories) test system, utilizing a Food and Drug Administration (FDA)-licensed disposable Endosafe-PTS test cartridge with a handheld spectrophotometer.
Sterility
Sterility testing on the final purified bulk D2C7-IT product was performed by the Duke University Hospital Radiopharmacy Laboratory. The final purified bulk D2C7-IT sample (0.5 mL) was aseptically added to the BBL Thioglycollate tube and incubated at 30-35°C for 14 days. The BBL Trypticase Soy Broth tube was inoculated with 0.5 mL of bulk D2C7-IT sample and incubated at 20-25°C for 14 days. Media was validated for the ability to grow test organisms and was determined to be sterile prior to use. Both the test and negative control tubes were examined for turbidity at specified intervals during the 14-day test period.
Chloramphenicol content
Chloramphenicol content was determined by Toxicology Associates Inc. (Columbus, OH), according to the standard gas chromatography/mass spectrometry (GC/MS) detection method. Chloramphenicol is a broad spectrum antibiotic that was extracted with a buffer and a solvent and derivatized with N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) with 1% trimethylchlorosilane (TCMS) and shot in GC/MS.
IPTG content
IPTG content was determined by Toxicology Associates Inc. (Columbus, OH), according to the standard GC/MS detection method. IPTG was extracted with a solvent and a buffer and derivatized with N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) at 70°C for 20 min and shot in GC/MS.
Vialing of the final purified bulk D2C7-IT product
The final purified bulk D2C7-IT product was sent to the Compounding Pharmacy at Duke University Medical Center for vialing. One milliliter of the final purified bulk D2C7-IT product, at a concentration of 120 μg/mL, was aliquoted into a 2-mL amber, serum type 1 glass vial with gray butyl Teflonfaced straight plug stoppers, and sealed with center disk tear-out aluminum. Sealed vials were affixed with a label designating the lot number and storage conditions and stored at −70 to −80°C. The final vialed D2C7-IT product was subjected to a product inspection, in which we examined the condition of the straight plug stoppers, the aluminum center disk, and the uniformity of the fill volume. We also checked for any cracks, verified that the product was appropriately labeled, and confirmed that the labels were securely applied. Finally, we ran another round of analytical release testing similar to the testing of the final purified bulk product (with the exception of E. coli DNA, chloramphenicol, and IPTG content assessments).
Flow cytometry
Indirect flow cytometry analysis was performed with the D2C7-IT or negative control P588-IT (P588-(scdsFv)-PE38KDEL). Briefly, 1 × 10 6 cells (murine Swiss 3T3 fibroblast cell line NR6, human epidermoid-carcinoma cell line A431p [expressing EGFRwt], or NR6M [NR6 cell line transfected with human EGFRvIII]) were suspended in 500 μL of PBS pH 7.4 (Invitrogen, Carlsbad, CA) containing 5% FBS (Invitrogen) (5% FBS/PBS). The D2C7-IT or negative control, P588-IT, was added to the cells at a concentration of 5 μg/mL, and the samples were incubated for 40 min at 4°C. After washing, the cells were incubated with rabbit antiPseudomonas exotoxin A antibody (Sigma, St. Louis, MO), followed by goat anti-rabbit-IgG-FITC antibody (Rockland, Limerick, PA). Stained cells were analyzed on a Becton Dickinson FACSort instrument equipped with CellQuest software (BD Biosciences, San Jose, CA).
Stability testing of the final vialed D2C7-IT product
Stability testing of the final vialed D2C7-IT product is being conducted under Protocol 2012-001 over a 5-year duration, from November 2012 to November 2017, by the DUMC/ AEAT program. Stability testing includes visual inspection; identity by SDS-PAGE; and verification of protein concentration, purity, potency, and pH (as described earlier) and will be tested at 0-, 3-, 6-, 9-, 12-, 18-, 24-, 30-, 36-, 42-, 48-, 54-, and 60-month time points. Sterility testing will be performed annually.
Results

D2C7-IT master cell bank production and validation
The E. coli strain BLR (DE3) was transformed with the pRB199-D2C7-(scdsFv)-PE38KDEL plasmid. On the basis of chloramphenicol and tetracycline resistance, ten positive clones labeled 11CT-20CT were selected for the screening of D2C7-IT expression. The culture identified as clone 18CT demonstrated the highest levels of D2C7-IT expression (data not shown) and was selected as the source of the D2C7-IT ACB (DsD2C7-PE38-KDEL clone 18CT BLR [DE3]).
From the D2C7-IT ACB, 240 MCB vials of D2C7-IT lot 212,001 (DsD2C7-PE38-KDEL MCB of clone 18 in E. coli BLR [DE3] 3-13-12) were prepared and stored frozen at −80°C. Quality control assessment of D2C7-IT MCB lot 212,001 confirmed the identity of the bacteria to be the nontoxic E. coli strain BLR (DE3) by comparative sequence analysis of genomic DNA (99.83%), by PFGE (>94% similarity), and through retention of the selection marker chloramphenicol. A sample of the pRB199-D2C7-(scdsFv)-PE38KDEL MCB (lot 212,001) was sequenced and was demonstrated to have 100% identity to the reference sequence. The sequencing data was used to derive the plasmid map included in Fig. 2 . Plasmid identity was also confirmed through 100% retention of the pRB199-D2C7-(scdsFv)-PE38KDEL construct in the transformed E. coli strain BLR (DE3) and by the generation of predicted fragment sizes upon restriction endonuclease digestion, including NdeI (linear), 5151 base pairs (bp), NdeI and EcoRI two fragments-3410 and 1883 bp, and NdeI and HindIII two fragments-4727 and 800 bp. Purity of the MCB bacterial culture was established due to the absence of contaminating bacterial growth in the differential agar, the ability of MCB to form viable colonies on LB-agar plates with a viability of 1.2 × 10 8 CFU/mL, and the bacterial copy number pre-test of the plasmid digest, which produced positive amplification of the gene of interest with fluorescent probes (306 plasmid copies/genome equivalent). Finally, the safety of the MCB was established by demonstrating the absence of the Shiga-like toxin/toxin gene, the absence of bacterial virus through plaque formation assay, and the absence of particles with bacteriophage morphology through negative staining and transmission electron microscopy examination.
Fermentation and purification of bulk D2C7-IT
To produce purified bulk lots of D2C7-IT, 12 rounds of seed buildup and fermentation (fermentation lot numbers 212,011-212,022) were performed using vials from the MCB. generation of a new lot of cell paste, which was processed for inclusion body isolation. Multiple washes of the inclusion body isolation with Triton X-100 detergent and Tris-EDTA buffer through centrifugation differentially removed a significant amount of contaminating host proteins as demonstrated in Fig. 3a, b . The final inclusion body yield from each round of fermentation was in the range of 1.7-4.3 g ( Table 1 ). The inclusion body pellets were solubilized in a strong denaturant (6 M guanidine-HCl), reduced with DTE, and diluted 100-fold in the refolding buffer. Individual batches of the refolded D2C7-IT protein (3-5-L refolding buffer) from each fermentation lot was dialyzed, filtered, and loaded onto a Q-Sepharose FF anion exchange column. The D2C7-IT protein bound to the Q-Sepharose column was eluted using a differential salt gradient, and 4 mL fractions of the eluate were examined for purity in SDS-PAGE gel. The majority of the D2C7-IT was contained in three to four Q-Sepharose eluate fractions, which were pooled for downstream processing. Representative D2C7-IT Q-Sepharose eluate fractions and the final purity of the combined Q-Sepharose fractions are shown in Fig. 4a, b . The 1.7 g of the inclusion body obtained from the first batch of D2C7-IT fermentation (lot 212,011) was purified through a total of six individual Q-Sepharose runs yielding a total of 86.3 mg of D2C7-IT. The pooled Q-Sepharose fractions were dialyzed in TSK buffer overnight at 4°C for size exclusion chromatography purification. After overnight dialysis, the protein was filtered and injected into a TSKgel SuperSW3000 gel filtration column equilibrated with TSK buffer, and the eluate corresponding to the major peak of D2C7-IT was analyzed in a SDS-PAGE gel. The fractions that contained only the D2C7-IT monomer (fractions 83-86 in Fig. 5) were pooled, concentrated, and loaded on to the ActiClean Etox column for endotoxin removal. The D2C7-IT eluate from the ActiClean Etox column was then dialyzed overnight at 4°C against DPBS CTS. A total of nine batches of bulk lots of D2C7-IT (lot nos. 212,032-212,040) were purified with a total yield of 307.75 mg, which were then transferred to 50-mL conical tubes, labeled, and stored at −80°C. The D2C7-IT purification process and the protein yields (fermentation lot nos. 212,032-212,040 and TSK-purified bulk lot nos. 212,032-212,040) at each step are summarized in Table 1 .
Preparation of the final purified bulk D2C7-IT product and analytical release testing
The final purified bulk D2C7-IT product was prepared by filtering and combining three batches of the intermediate bulk product, specifically lot 212,033, lot 212,034, and lot 212,035, for a total volume of 118 mL. The volume was adjusted to 250 mL by adding 132 mL of DPBS CTS, and the protein concentration was initially determined to be 0.36 mg/mL using the Pierce Coomassie Plus Assay. However, since the curve was not linear in this initial assessment, the bulk product was further diluted to 500 mL by the addition of 250 mL DPBS CTS. The protein concentration of the diluted pool was determined to be 0.166 mg/mL for a total of 83 mg of protein Samples were harvested at the end of the induction period, and different volumes (5 and 15 μL) of crude bacterial lysate were analyzed in an SDS-PAGE gel. M molecular weight standard. b Of the D2C7-IT inclusion body, 25 μL was analyzed in an SDS-PAGE gel during the final TE 50/20 buffer wash. M molecular weight standard, IB inclusion body final volume was adjusted to 600 mL by adding 100 mL DPBS-CTS, and the final concentration was determined to be 0.123 mg/mL. The final purified bulk D2C7-IT was designated as lot 212,041, and twenty 1-mL vials were frozen and stored at −80°C as the purified bulk reference standards. The purified bulk reference standard (D2C7-IT lot 212,041) was subjected to analytical release testing as described in the BMaterials and methods^section, and the results are presented in Fig. 6 . The purified bulk D2C7-IT lot 212,041 was a colorless clear liquid with no particles at 25°C. The purified bulk D2C7-IT lot 212,041 generated a single band corresponding to 61 and 62.5 kDa in a reduced and non-reduced SDS-PAGE analysis, respectively. The purified bulk D2C7-IT lot 212,041 had a final protein concentration of 0.123 mg/mL. The purified D2C7-IT lot 212,032 was used as a reference standard for the assessment of cytotoxicity (IC 50 ) of the purified bulk D2C7-IT lot 212,041. The cytotoxicity of the reference standard D2C7-IT lot 212,032 and purified bulk D2C7-IT lot 212,041 on mutant EGFRvIII-expressing NR6M cells were 0.310 and 0.410 ng/mL and on EGFRwt-expressing A431p cells were 0.038 and 0.049 ng/mL, respectively. The purified bulk D2C7-IT lot 212,041 had 98.7% monomers and 1.3% fragments by HPLC-SEC analysis. The isoelectric point of the purified bulk D2C7-IT lot 212,041 was 5.3. The purified bulk D2C7-IT lot 212,041 had a pH of 7.4, DNA content of <20 pg/mL, and endotoxin levels equivalent to 1.09 EU/mL and exhibited no growth in a sterility assay. The chloramphenicol content of lot 212,041 of the final purified bulk product was 1.2 μg/mL. According to the laboratory report from Toxicology Associates Inc., Columbus, OH, the levels of chloramphenicol in biological products needs to be >25 μg/mL to be toxic in humans. In the clinical study, we have proposed to infuse patients with a maximum of 1,143,504 ng of D2C7-IT, which is the equivalent to 9.53 mL of lot 212,041. Thus, the maximal potential exposure of chloramphenicol to patients in the clinical study will be 11.04 μg, which is below the toxic range of >25 μg/mL. Therefore, the levels of chloramphenicol in lot 212,041 were considered to be non-toxic. Additionally, the level of IPTG in lot 212,041 was undetectable as it was below the limit of sensitivity. Preparation of the final vialed D2C7-IT product and analytical release testing
Upon clearance of the analytical release testing, the remaining 580 mL of the purified bulk D2C7-IT lot 212,041 was sent to the Compounding Pharmacy at Duke University Medical
Center for vialing. The final product contained approximately 1 mL of purified D2C7-IT/vial at a concentration of 120 μg/ mL in DPBS CTS. A total of 560 vials labeled as lot 211,131 were prepared, delivered, and stored at ≤−70°C. The final vialed product, D2C7-IT lot 211,131, underwent similar analytical release testing as the final purified bulk product, with
Chromatographic profile and coomassie-stained SDS-PAGE gel of D2C7-IT TSK fractions the exception of the assessment for DNA, chloramphenicol, and IPTG content, since these tests have already been performed. The analytical release testing results for the final vialed product, D2C7-IT lot 211,131, are presented in Fig. 7 . The final vialed D2C7-IT lot 211,131 was a colorless clear liquid with no particles at 25°C. The final vialed D2C7-IT lot 211,131 generated a single band corresponding to 61 and 62.5 kDa in a reduced and non-reduced SDS-PAGE analysis, respectively. The final vialed D2C7-IT lot 211,131 had a final protein concentration of 0.12 mg/mL. The purified D2C7-IT lot 212,032 was used as reference standard for the assessment of cytotoxicity (IC 50 ) of the final vialed D2C7-IT lot 211,131. The cytotoxicity of the reference standard D2C7-IT lot 212,032 and final vialed D2C7-IT lot 211,131 on mutant EGFRvIII-expressing NR6M cells were 0.210 and 0.120 ng/ mL, respectively. The cytotoxicity of the reference standard D2C7-IT lot 212,032 and final vialed D2C7-IT lot 211,131 on EGFRwt-expressing A431p cells were 0.031 and 0.041 ng/ mL, respectively. The final vialed D2C7-IT lot 211,131 had 97.7% monomers and 2.1% fragments by HPLC-SEC analysis. The isoelectric point of the final vialed D2C7-IT lot 211,131 was 5.3. The final vialed D2C7-IT lot 211,131 had a pH of 7.4 and endotoxin levels equivalent to 1.26 EU/mL and exhibited no growth in a sterility assay.
Antigen specificity of the final vialed product, D2C7-IT lot 211,131
To determine the target antigen specificity of the final vialed product, D2C7-IT lot 211,131, the ability of D2C7-IT to bind to human EGFRwt and EGFRvIII proteins expressed on the cell surface was assessed by indirect flow cytometry (Fig. 8) . Fig. 6 Purified bulk D2C7-IT lot 212,041 analytical release testing summary. The purified bulk reference standard, D2C7-IT lot 212,041, was subjected to analytical release testing including product inspection, identity, content, potency, purity, and safety Flow cytometry analysis revealed that the D2C7-IT lot 211,131 bound to both the EGFRwt-expressing A431p cells (Fig. 8b) and the EGFRvIII-expressing NR6M cells (Fig. 8c) . The parental NR6 cells (Fig. 8a) and the non-specific P588-IT were used as negative controls, which confirmed the binding specificity of D2C7-IT lot 211,131 to native EGFRwt and EGFRvIII protein molecules expressed on human tumor and transfected mouse cell lines.
Stability testing of the final vialed product, D2C7-IT lot 211,131
Stability testing of the final vialed product, D2C7-IT lot 211,131, is being conducted over a 5-year period, from November 2012 to November 2017, by the DUMC/AEAT program. Visual appearance, protein concentration, purity, potency, and pH are being assessed by the methods outlined in the BMaterials and methods^section and will be tested at 0-, 3-, 6-, 9-, 12-, 18-, 24-, 30-, 36-, 42-, 48-, 54 -, and 60-month time points. Sterility testing will be performed annually. Specifications for each of the stability tests have been determined and are as follows: (1) the visual appearance specification requires that the results are clear with no foreign matter, (2) the protein concentration by Pierce Coomassie Plus used to determine protein content should specify a range of 0.12 mg/ mL ± 0.01 mg/mL, (3) the major bands and the banding pattern reported by SDS-PAGE should conform to the standard reference (reference standard lot 212,041), (4) the results Fig. 7 Final vialed D2C7-IT lot 211,131 analytical release testing summary. The final vialed product, D2C7-IT lot 211,131, was subjected to analytical release testing including product inspection, identity, content, potency, purity, and safety reported by IEF gel should conform to the standard reference (reference standard lot 212,041), (5) purity results as determined by HPLC-SEC must meet a specification of ≥95% total protein amounts of monomer, (6) the results of the cytotoxicity assay used to determine the potency of the product must conform to the standard reference (reference standard lot 212,041), (7) the product must be found sterile, and (8) the acceptable pH range is 7.4 ± 0.4. The stability tests performed, the assay specifications, and the available test results are summarized in Table 2 , and the 42-month stability data is presented in Fig. 9 . The results indicated that lot 211,131 of the final vialed product met the specifications set for the required assays through 42 months.
Discussion
We have successfully manufactured a GLP-grade D2C7-(scdsFv)-PE38KDEL immunotoxin for a phase I/II clinical trial in patients with recurrent glioblastoma (NCT02303678, D2C7 for Adult Patients with Recurrent Malignant Glioma; clinicaltrials.gov). This is the first study that reports the quality control and stability testing (for a 42-month period since the date of manufacture) of a GLP-grade D2C7-(scdsFv)-PE38KDEL immunotoxin, which is currently being tested in clinical trials.
High levels of D2C7-IT expression in E. coli resulted in aggregation of the expressed protein molecules into inclusion bodies. From a total of nine fermentation runs, we generated a total of 26.3 g of inclusion body. Solubilization of the D2C7-IT inclusion body was achieved using a high concentration of guanidine-HCl, which was then refolded by removal of the solubilization agent through dilution in refolding buffer. Twenty-six grams of the D2C7-IT inclusion body was refolded by dilution in a total of 260 L of refolding buffer. Refolded D2C7-IT was dialyzed and then purified through a strong anion-exchange chromatographic step followed by a size exclusion chromatographic step. The total yields of purified D2C7-IT after anion exchange and size exclusion chromatographic steps were 926.9 and 356.2 mg, respectively. Because of the use of a bacterial expression system, endotoxin contamination was involved in the D2C7-IT preparation. Thus, preparation required multiple washes with detergent to remove the majority of this contaminant before polishing on secondary chromatography columns and endotoxin removal resins. The total D2C7-IT after endotoxin removal was 341.96 mg, and the final yield of the GLP grade D2C7-IT after dialysis against DPBS CTS was 307.75 mg. As discussed and agreed upon with the FDA at our pre-IND meeting, the final purified bulk product was made by combining purified intermediate bulk lots 212,033, 212,034, and 212,035, which were subjected to extensive analytical release testing both pre-and post-vialing. A quantitative acceptance criterion, with an upper and lower limit, for the potency assay (cytotoxicity assay) used for release and stability testing of the final purified bulk product (lot 212,041) and the final vialed product (lot 211,131) was determined by a statistician. The conclusions are as follows: (1) final purified bulk (lot 212,041) on A431p cells based upon four available IC50 observations, with a mean = 40 and SD = 7.39, 68% prediction interval 32.7, 47.4; (2) final vialed product (lot 211,131) on A431p cells based upon 104 IC50 observations, with a mean = 40.35 and SD = 14.26, 68% prediction interval 26.1, 54.4; (3) final purified bulk (lot 212,041) on NR6M cells based upon four available IC50 observations, with a mean = 306.3 and SD = 114.1, 68% prediction interval 192.2, 420.4; and (4) final vialed product (lot 211,131) on NR6M cells based upon 40 IC50 observations, with a mean = 432.9 and SD = 161.4, 68% prediction interval 271.5, 594.3. Upon the request from FDA following the pre-IND comments, SDS-PAGE and IEF-gel analyses were added to the stability testing protocol of the final vialed product (lot 211,131). These additional tests were added to the ongoing stability protocol at the 9-month time point. Therefore, data for these two tests are reported in the stability results summary in Table 2 , beginning at 9 months of stability testing. Additionally, upon consultation with the Duke Translational Medicine Institute Regulatory Affairs group, the expiration date of the final vialed product (lot 211,131) was extended from 48 to 60 months after the completion of the 42-month stability testing. Similarly, the expiration date of the final vialed product (lot 211,131) will be extended from 60 to 72 months after the completion of the 66-month stability testing.
Major challenges associated with the production of dsFv-PE38 immunotoxins such as HA22, SS1P, MR1-1, and 55.1 include the expressions of V H and V L fragments as individual components and mixing the reduced V H and V L inclusion body solutions at a 1:1-M ratio prior to refolding (Reiter et al. 1996a, b; Reiter and Pastan 1996; Ochiai et al. 2008 ). Subsequent to the refolding process, it is critical that the individual V H and V L fragments are separated from the correctly refolded dsFv-PE38 immunotoxin fragment, making this a key quality control step during the ion exchange and size exclusion chromatographic purification process (Jiang et al. 2013 ). This two-step purification process frequently results in low yield because of the inefficient purification of the V H or V L fragments from the completely refolded dsFv-PE38 immunotoxin (Jiang et al. 2013) . A more recent and improved three-step purification process involving ammonium sulfate precipitation, phenyl HP hydrophobic interaction, and ion exchange chromatographic purification was described, which resulted in a significant increase in the final yield of the purified dsFv-PE38 immunotoxins MR1-1 and HA22 (Jiang et al. 2013) . However, even with the improved three-step purification process, the individual V H and V L fragments had to be expressed separately and had to be removed from the final current Good Manufacturing Practice (cGMP)-grade dsFv-PE38 immunotoxin (Jiang et al. 2013) . In contrast to the dsFv-PE38 immunotoxins, the D2C7-(scdsFv)-PE38KDEL immunotoxin is expressed as a single-chain, disulfidestabilized immunotoxin fragment (scdsFv-PE38KDEL) (Chandramohan et al. 2013) . Fusing the V H and V L fragments via a 15 amino acid linker fragment and increasing the stability of the linked V H and V L fragments via a disulfide bond (scdsFv) offers the convenience of a single-batch expression while simultaneously avoiding the individual V H and V L fragment contamination in the purified D2C7-(scdsFv)-PE38KDEL immunotoxin. The final yield of the GLP-grade D2C7-(scdsFv)-PE38KDEL immunotoxin was approximately 8-10%. We believe that if scaled up to an 80-L fermentation batch, the yield of the D2C7-(scdsFv)-PE38KDEL immunotoxin could be increased to meet the cGMP requirements for a phase III clinical trial.
A clinical supply of large quantities of immunotoxins such as D2C7-IT is highly desirable (Hassan et al. 2007; Kreitman et al. 2009; Kreitman et al. 2012; Bao et al. 2016; Kreitman et al. 2016 ). This particular protein typifies the difficulties in supplying single-chain, disulfide-stabilized immunotoxins due to the challenges in producing D2C7-IT at a higher yield and purity under GLP conditions. The main difficulty we encountered during the manufacturing process was the degradation of D2C7-IT when stored at 4°C in the absence of the carrier protein. We had to forego three fermentation batches (lots 212,019, 212,020, and 212,021) after Q-Sepharose purification due to D2C7-IT degradation at 4°C. We overcame this problem by storing intermediate purification products at −80°C. Despite these challenges, we were able to produce 307.75 mg of a GLP-grade D2C7-IT from a total of nine, 8-L fermentation runs. Most importantly, this material is currently being tested in a phase I/II clinical trial in patients with recurrent glioblastoma, and we anticipate that it will save many lives.
